DigestRedComo funciona
Red
/
Empresas
Ha
No verificado

Hansa Biopharma AB

Sobre qué escribimos

BiologíaEconomíaEmpresasFarmacéuticaSanidad

20 Comunicados de prensa

Ver todos los comunicados de prensa
14/05/2025
Farmacéutica
Banca
Sanidad
Economía
Start-up
Finanzas
Biología
Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
13/05/2025
Farmacéutica
Sanidad
Economía
Gestión empresarial
Administración de Empresas
Biología
Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
24/04/2025
Farmacéutica
Sanidad
Empresas
Biología
Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
21/03/2025
Farmacéutica
Sanidad
Economía
Biología
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
11/03/2025
Farmacéutica
Sanidad
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
06/02/2025
Farmacéutica
Sanidad
Empresas
Biología
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
07/01/2025
Farmacéutica
Sanidad
Biología
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
17/12/2024
Farmacéutica
Sanidad
Biología
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
05/12/2024
Farmacéutica
Sanidad
Economía
Start-up
Biología
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0
03/12/2024
Farmacéutica
Sanidad
Economía
Start-up
Biología
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
Fuente
Hansa Biopharma AB
Editor
PR News Wire
1,00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0